Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT00452790

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

Conditions: Pneumococcal Infections

Sex: All

Ages: 42 Days – 72 Days

Healthy volunteers: Yes

Phase: PHASE3

Enrollment: 708

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Location: Sector-12 Chandigarh

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in India.

Eligibility Criteria

Inclusion Criteria 1. Healthy infants aged 6 weeks (42-72 days) at time of enrolment 2. Available for the entire study period Exclusion Criteria 1. Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis or Hib vaccines 2. A previous anaphylactic reaction to any vaccine or vaccine-related component 3. Contraindication to vaccination with pneumococcal, Hib, diphtheria, tetanus, pertussis, polio, hepatitis B or measles vaccines

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00452790). StuddyBuddy aggregates publicly available trial information.